Back
 JDM  Vol.4 No.4 , November 2014
The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients
Abstract: Glucagon-like peptide 1 (GLP-1) is a hormone, inducing glucose-dependent stimulation of insulin secretion from beta cells. Liraglutide acts as a GLP-1 receptor agonist. To assess the effect of liraglutide on the beta cell function, we performed oral glucose tolerance tests in 7 subjects with type 2 diabetes before and after treatment of liraglutide. Moreover, we performed same study again in 4 subjects at 6 months after induction. Liraglutide significantly increased area under the Curve (AUC) of plasma insulin level after glucose loading and significantly decreased AUC of plasma glucose level, compared with before induction. HOMA-beta was significantly increased, whereas insulinogenic index was not changed. HOMA-R was not affected but Matsuda index was significantly decreased after induction of liraglutide. Disposition index was not altered significantly, but tendency of improvement was observed. Glucose tolerance tests revealed that those effects of liraglutide were continued for 6 months after induction. These results showed that treatment of liraglutide could improve insulin secretion but early phase of insulin secretion was not improved. The results suggest that liraglutide is likely to improve beta-cell function, but this effect is still inadequate by six-month treatment.
Cite this paper: Suzuki, T. , Hirai, K. , Chen, Y. and Hashimoto, K. (2014) The Short- and Long-Term Effect of Liraglutide on the Beta Cell Function in Type 2 Diabetic Patients. Journal of Diabetes Mellitus, 4, 334-340. doi: 10.4236/jdm.2014.44046.
References

[1]   Holst, J.J. (2007) The Physiology of Glucagon-Like Peptide 1. Physiological Reviews, 87, 1409-1439. http://dx.doi.org/10.1152/physrev.00034.2006

[2]   Turton, M.D., O’Shea, D., Gunn, I., Beak, S.A., Edwards, C.M., Meeran, K., et al. (1996) A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding. Nature, 379, 69-72.
http://dx.doi.org/10.1038/379069a0

[3]   Wishart, J.M., Horowitz, M., Morris, H.A., Jones, K.L. and Nauck, M.A. (1998) Relation between Gastric Emptying of Glucose and Plasma Concentrations of Glucagon-Like Peptide-1. Peptides, 19, 1049-1053. http://dx.doi.org/10.1016/S0196-9781(98)00052-7

[4]   Agerso, H., Jensen, L.B., Elbrond, B., Rolan, P. and Zdravkovic, M. (2002) The Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of NN2211, a New Long-Acting GLP-1 Derivative, in Healthy Men. Diabetologia, 45, 195-202. http://dx.doi.org/10.1007/s00125-001-0719-z

[5]   Shimoda, M., Kanda, Y., Hamamoto, S., Tawaramoto, K., Hashiramoto, M., Matsuki, M., et al. (2011) The Human Glucagon-Like Peptide-1 Analogue Liraglutide Preserves Pancreatic Beta Cells via Regulation of Cell Kinetics and Suppression of Oxidative and Endoplasmic Reticulum Stress in a Mouse Model of Diabetes. Diabetologia, 54, 1098-1108. http://dx.doi.org/10.1007/s00125-011-2069-9

[6]   Degn, K.B., Juhl, C.B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., et al. (2004) One Week’s Treatment with the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and Alpha- and Beta-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes. Diabetes, 53, 1187-1194.
http://dx.doi.org/10.2337/diabetes.53.5.1187

[7]   Matsuda, M. and DeFronzo, R.A. (1999) Insulin Sensitivity Indices Obtained from Oral Glucose Tolerance Testing: Comparison with the Euglycemic Insulin Clamp. Diabetes Care, 22, 1462-1470. http://dx.doi.org/10.2337/diacare.22.9.1462

[8]   Kelly, L.A., Lane, C.J., Weigensberg, M.J., Koebnick, C., Roberts, C.K., Davis, J.N., et al. (2007) Parental History and Risk of Type 2 Diabetes in Overweight Latino Adolescents: A Longitudinal Analysis. Diabetes Care, 30, 2700-2705. http://dx.doi.org/10.2337/dc07-0050

[9]   Larsen, M.O., Rolin, B., Gotfredsen, C.F., Carr, R.D. and Holst, J.J. (2004) Reduction of Beta Cell Mass: Partial Insulin Secretory Compensation from the Residual Beta Cell Population in the Nicotinamide-Streptozotocin Gottingen Minipig after Oral Glucose in Vivo and in the Perfused Pancreas. Diabetologia, 47, 1873-1878. http://dx.doi.org/10.1007/s00125-004-1546-9

[10]   Butler, A.E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R.A. and Butler, P.C. (2003) Beta-Cell Deficit and Increased Beta-Cell Apoptosis in Humans with Type 2 Diabetes. Diabetes, 52, 102-110. http://dx.doi.org/10.2337/diabetes.52.1.102

[11]   Buteau, J., Foisy, S., Joly, E. and Prentki, M. (2003) Glucagon-Like Peptide 1 Induces Pancreatic Beta-Cell Proliferation via Transactivation of the Epidermal Growth Factor Receptor. Diabetes, 52, 124-132. http://dx.doi.org/10.2337/diabetes.52.1.124

[12]   Friedrichsen, B.N., Neubauer, N., Lee, Y.C., Gram, V.K., Blume, N., Petersen, J.S., et al. (2006) Stimulation of Pancreatic Beta-Cell Replication by Incretins Involves Transcriptional Induction of Cyclin D1 via Multiple Signalling Pathways. Journal of Endocrinology, 188, 481-492.
http://dx.doi.org/10.1677/joe.1.06160

[13]   Hui, H., Nourparvar, A., Zhao, X. and Perfetti, R. (2003) Glucagon-Like Peptide-1 Inhibits Apoptosis of Insulin-Secreting Cells via a Cyclic 5’-Adenosine Monophosphate-Dependent Protein Kinase A- and a Phosphatidylinositol 3-Kinase-Dependent Pathway. Endocrinology, 144, 1444-1455.
http://dx.doi.org/10.1210/en.2002-220897

 
 
Top